KoBioLabs KRX:348150KOSDAQ
고바이오랩 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, KoBioLabs reported revenue of ₩21.8bn, up 23.8% year on year, and an operating loss of ₩2.0bn. KoBioLabs (고바이오랩) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
KoBioLabs quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩21.8bn | +23.8% | −₩2.0bn margin −9.2% | −₩3.9bn |
| Q1 2026 | ₩19.2bn | +11.1% | −₩2.7bn margin −13.9% | −₩195m |
| Q4 2025 derived | ₩15.1bn | -14.4% | −₩3.0bn margin −19.6% | −₩1.6bn |
| Q3 2025 | ₩19.3bn | +13.9% | −₩423m margin −2.2% | ₩856m |
| Q2 2025 | ₩17.6bn | -6.9% | −₩2.8bn margin −15.9% | −₩3.2bn |
| Q1 2025 | ₩17.3bn | +16.0% | −₩3.5bn margin −20.0% | −₩3.1bn |
| Q4 2024 derived | ₩17.7bn | +66.8% | −₩1.6bn margin −9.2% | −₩1.1bn |
| Q3 2024 | ₩16.9bn | +119.6% | −₩1.3bn margin −7.7% | −₩1.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
KoBioLabs top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest KoBioLabs news Korean headlines
No articles yet.